Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial
Olaparib maintenance therapy improved PFS in patients with metastatic pancreatic adenocarcinoma characterized by a deleterious BRCA1/2 mutation.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
The Incidence of Some Obesity-Related Cancers Is Increasing Among Young Adults
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Study results suggest a new combination regimen could become the standard of care for some patients.
Phase 1, 2 Trials to Assess Imaging System for Gastrointestinal Cancer Detection
Researchers are seeking to assess the initial safety and efficacy of LUM015 imaging of colorectal, pancreatic, and esophageal cancers using the LUM 2.6 imaging device.
Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer
Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.
Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer
The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.
Pancreatic Tumor Bacteria Found To Be Similar to Microbes Located in the Mouth
The bacterial strains found in oral samples may be representative of the types of strains that exist in the tumor microbiomes of patients with pancreatic or GI disease.
Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer
Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.
Pancreatic Cancer Risk Linked to Number of First-Degree Relatives Who Are Affected by Cancer
Pancreatic risk rises in a dose-response manner with increasing number of affected first-degree relatives.
KRAS Mutations May Influence Location, Local Recurrence of Resected Pancreatic Cancer
Different KRAS mutations may be associated with differing primary tumor locations and patterns of local recurrence in resected pancreatic cancer.
New Molecular Features May Provide Insight Into Primary Pancreatic Cancer
Molecular features of primary and metastatic PDAC may provide new insight into disease management and drug development.
Characterization of Tumor Stromal Cells at the Single-Cell Level Using Machine Learning
Researchers describe SuperCT, a predictive framework for the identification of tumor stromal cell type based on scRNA-seq data.
Pancreatic Cancer Organoids May Be a Platform to Study Response to Immunotherapies
Organoids propagated from pancreatic tumor cells may provide a platform to evaluate patient response to immune checkpoint inhibitors.
New-Onset Diabetes Associated With IPMN Progression
New-onset diabetes, but not baseline diabetes, is associated with an increased risk of progression of intraductal papillary mucinous neoplasms.
Moffitt’s Basal-Like Gene Signature Associated With Poor Survival in Pancreatic Cancer
The Moffitt gene set identifies a poor prognostic group of patients with locally advanced or metastatic pancreatic cancer.
Pancreatic Cancer CTCs Harvested by Leukapheresis Yield Organoids
Organoids can be propagated from CTCs from patients with pancreatic cancer, potentially offering an approach to study treatment resistance.
Hepatitis B Infection May Increase the Risk for Pancreatic Cancer
Investigators assessed the association of hepatitis B infection and pancreatic cancer, along with predictors of pancreatic cancer and mortality.
Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
Prior to this study, there were no conclusive data directly comparing these regimens.
Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling
Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.
Eosinophil-to-Lymphocyte Ratio Associated with Shorter Survival in Pancreatic Cancer
Are systemic inflammatory biomarkers in the blood potential prognostic markers of overall survival in pancreatic cancer?
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
